Clinical Trials Logo

Clinical Trial Summary

The SchistoSAM study is an open label, two-arm, individually-randomized controlled trial with a non-inferiority design, conducted in northern Senegal. The study aims at determining if the efficacy of one and of repeated courses of artesunate-mefloquine (AM) is respectively similar to or higher than that of a standard praziquantel (PZQ) treatment. Secondly, the study will assess if novel DNA- and antigen-based diagnostics are more accurate than microscopy in assessing antischistosomal treatment response.


Clinical Trial Description

The SchistoSAM study is an open label, two-arm, individually-randomized controlled trial with a non-inferiority design, conducted in northern Senegal. The study aims at determining if the efficacy of one and of repeated courses of artesunate-mefloquine (AM) is respectively similar to or higher than that of a standard praziquantel (PZQ) treatment. Secondly, the study will assess if novel DNA- and antigen-based diagnostics are more accurate than microscopy in assessing antischistosomal treatment response. For this purpose, 726 school children, aged 6-14 years old and infected with Schistosoma (as demonstrated by presence of eggs in stool and/or urine) will be randomized in one of the following arms: 1. AM, available in fixed dose tablets of 25/50 mg and 100/200 mg will be administered once daily for three days in a dose closest to 4 mg/kg artesunate and 8 mg/kg mefloquine. This treatment course will be repeated 2 times at 6-week intervals. 2. PZQ, available in tablets of 600 mg, will be administered as a single dose of 40 mg/kg. Trial participants will be regularly followed-up: 1. At each dose administration 2. At day 7 after each dose for follow-up of safety 3. At week 4, 10 and 16 for parasitological assessment and follow-up of safety 4. At week 6 and 12 for clinical assessment before the second and third drug administration (only in the AM arm) 5. At week 24 and 48 for assessment of Schistosoma spp. and malaria infection and associated morbidity (compared to baseline) ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03893097
Study type Interventional
Source Institute of Tropical Medicine, Belgium
Contact
Status Completed
Phase Phase 3
Start date October 14, 2019
Completion date March 4, 2021

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05999825 - Sm-p80 Schistosomiasis Challenge Study Phase 2
Active, not recruiting NCT03910972 - Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults Phase 1/Phase 2
Completed NCT05085470 - Repeated Controlled Human Schistosoma Mansoni Infection N/A
Completed NCT02755324 - Single-sex Controlled Human Schistosomiasis Infection: Safety and Dose Finding N/A
Completed NCT01054651 - A Randomised Trial of Artesunate-sulfamethoxypyrazine/Pyrimethamine Versus Praziquantel for the Treatment of S. Mansoni Phase 3
Completed NCT04679831 - Clinical Evaluation of Ujiplus® Against Schistosoma Mansoni Phase 2/Phase 3
Withdrawn NCT02810613 - Leiden University Medical Center Mini Donor Bank N/A
Completed NCT02162875 - Schistosoma Mansoni in Mwanza Region, Tanzania N/A
Recruiting NCT06311344 - Filling Key Research Gaps With Clinical Implications in Mansonellosis and Schistosomiasis: a Network Approach N/A